NCT02810964View on ClinicalTrials.gov

Sulforaphane to Reduce Symptoms of Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

November 11, 2019

Study Completion Date

November 11, 2019

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Sulforaphane Nutraceutical

Sulforaphane Nutraceutical 6 tablets by mouth daily

DRUG

Identical-appearing Placebo

Identical-appearing Placebo 6 tablets by mouth daily

Trial Locations (1)

21204

Sheppart Pratt Health System, Towson

All Listed Sponsors
lead

Sheppard Pratt Health System

OTHER

NCT02810964 - Sulforaphane to Reduce Symptoms of Schizophrenia | Biotech Hunter | Biotech Hunter